Pilot cml autograft/glivec (STI571)/Intron A trial

This study looks at a combination treatment for a type of blood cancer called CML (chronic myeloid leukaemia) or a related condition called ALL (acute lymphoblastic leukaemia) that involves a specific chromosome abnormality. The treatment combines a stem cell transplant using the patient's own stem cells (autologous transplant) with two medicines: Glivec (imatinib) and Intron A (interferon). Researchers want to see how safe and effective this combination is. You may be eligible if: - You are between 18 and 70 years old - You have been diagnosed with Ph chromosome-positive CML that is not in first chronic phase, or Ph-positive ALL, or CML that has become resistant to Glivec - You have stored (frozen) stem cells available from a previous collection - Your liver, kidney, and bone marrow function are within acceptable levels - You have given written informed consent You may NOT be eligible if: - There are no specific exclusion criteria listed beyond meeting all inclusion requirements and standard safety measures Talk to your doctor about whether this trial might be right for you.